Close Menu

Melissa Lueke, Eric Rasmussen, Bryan Baldasare

Dec 12, 2018

Melissa Lueke, executive VP and CFO at Meridian Bioscience, will retire from her position effective Jan. 1, 2019. Lueke, who has been at Meridian for 20 years, will remain with the firm in a paid financial consulting role with a renewable contract of three years.

Meridian also promoted Eric Rasmussen from his role as EVP of corporate development to the position of EVP, CFO, and principal financial officer, also effective Jan. 1, 2019. Rasmussen was hired by Meridian in June of 2018, and previously served in corporate development and financial leadership roles at Lear Corporation, an automotive seating and electrical systems supplier. Rasmussen has also served on the advisory board of Exploragen, a DNA lifestyle company.

Meridian has also promoted Bryan Baldasare to the role of Chief Accounting Office. Baldasare has been with Meridian since 2000, and most recently served as Senior VP, Corporate Controller and Treasurer.

More Like This

Oct 10, 2019

Stilla Technologies: Ruth Szebries

Stilla Technologies has appointed Ruth Szebries as general manager and vice president of commercial operations for its newly established US subsidiary in Beverly, Massachusetts. Szebries will oversee operations in the Americas for the Paris, France-based digital PCR developer. Her previous life science industry experience includes positions at Applied Biosystems and Beckman Coulter, leading the US subsidiaries of BGI and Exiqon, and serving for three years at Qiagen, most recently as that firm's senior director for global market development.

Oct 08, 2019

Grail: Matthew Young

Grail has appointed Matthew Young as chief operating officer. Young joins Grail from Jazz Pharmaceuticals, where he most recently served as executive VP and CFO. Prior to Jazz, Young worked in investment banking for about 20 years in positions at Barclays Capital, Citigroup Global Markets, and Lehman Brothers. He currently is a board member at PRA Health Sciences. Young is also a lead independent director and chairman of the audit committee of CytomX Therapeutics. 

Oct 08, 2019

Biodesix: James Jett

Biodesix has appointed James Jett as chief medical officer. Jett previously served as CMO at Oncoimmune. Before Onocimmune, Jett worked as a professor of medicine at the Mayo Medical School and the University of Pittsburgh. Jett has also served as a consultant for the National Cancer Institute and as the editor in chief of the Journal of Thoracic Oncology from 2006 to 2013. 

Oct 04, 2019

Grail: Marissa Song

Grail has appointed Marissa Song as its general counsel and corporate secretary. Prior to Grail, Song worked at Gilead Sciences for 14 years, where she most recently served as VP of corporate legal. Before Gilead, Song was a corporate associate at Latham & Watkins LLP. She also currently serves on the board of the Disability Rights Legal Center.

Oct 04, 2019

Meridian Bioscience: Bryan Baldasare

Meridian has appointed Bryan Baldasare to chief financial officer. He was previously the interim CFO, corporate controller, and treasurer and is currently also the executive vice president and chief accounting officer. Baldasare has been with Meridian since 2000, and before that he was a senior audit manager at Arthur Andersen LLP. 

Oct 02, 2019

NanoString Technologies: Mark Winham

Nanostring has appointed Mark Winham as senior vice president of operations. Winham worked for more than 10 years in manufacturing for Applied Biosystems and Life Technologies, serving in roles of increasing responsibility from senior director to vice president of global manufacturing. More recently, he served as chief scientific and operating officer at Wamberg Genomic Advisors. Prior to that, he was chief operating office for Human Longevity, and also previously served as COO of Millennium Health.

Oct 01, 2019

Precision Biosciences: Nicholas Riddle

Precision Biosciences announced today that it has appointed Nicholas Riddle as VP, financial strategy and investor relations. Prior to Precision, Riddle served as executive director at J.P. Morgan. Before that, Riddle held the role of public market equity analyst at York Capital Management.

Sep 26, 2019

Becton Dickinson: Vincent Forlenza, Thomas Polen

Becton Dickinson announced that Vincent Forlenza will retire from his position as of Jan. 28, 2020. Forlenza, who has been with BD for 40 years and has led the company as CEO since 2011, will continue to serve as executive chairman of its board of directors. Thomas Polen, the firm's chief operating officer, will take over as CEO. 

Sep 26, 2019

Cofactor Genomics: Natalie LaFranzo

Cofactor Genomics has promoted Natalie LaFranzo to Vice President of Market Development. She has been with the company for three years. Previously, she held roles in product management at Horizon Discovery and in marketing and communications at Red Rock Labs. LaFranzo will also head Cofactor's new predictive immune modeling center in Cambridge, Massachusetts. The facility will be the company's hub for the research and operations team working with Boston-based pharma, RNA, precision medicine, and immunotherapy companies. 

Sep 25, 2019

Myriad Genetics: Colleen Reitan, Lee Newcomer

Myriad Genetics has elected Colleen Reitan and Lee Newcomer to its board of directors.

Reitan has spent more than 32 years working in the Blue Cross Blue Shield system, most recently as president of plan operations for Health Care Service Corporation (HCSC), a health plan covering 16 million lives. Prior to BCBS, Reitan held several roles of increasing responsibility including executive VP and chief operating officer for HCSC and president and chief operating officer of BCBS of Minnesota. She currently serves on the boards of Alnylam Pharmaceuticals and Cricket Health.

Newcomer is a board-certified oncologist who most recently served as senior VP of oncology and genetics for UnitedHealthcare. Previously, he was chief medical officer and senior VP of health policy and strategy at UnitedHealth Group. He also served as chief medical officer at Vivius. Newcomer currently serves on the board of Cellworks Group and Intervention Insights.

Sep 23, 2019

Oncimmune: Tariq Sethi, Matthew Luttrel, Cléa Rosenfeld

Oncimmune has appointed several members to the firm, including Tariq Sethi as CSO, Matthew Luttrell as chief commercial officer, and Cléa Rosenfeld as its head of investor relations.

Prior to Oncimmune, Sethi held the roles of chief physician scientist, VP of clinical discovery at AstraZeneca, and emeritus professor of respiratory medicine at King's College London. Prior to that, he served as VP of respiratory autoimmunity translational medicine unit at AstraZeneca, as well as professor of respiratory medicine and lung cancer at Edinburgh University. Sethi is also the founder of Galecto Biotech. He will also join Oncimmune's senior leadership team starting Oct. 1.

Before Oncimmune, Luttrell served in senior roles at Takeda. Prior to Takeda, has held roles at Novo Nordisk, Gilead, GlaxoSmithKline, and Shire. He will also join Oncimmune's senior leadership team starting Oct. 1.

Rosenfeld is a senior investor relations and corporate communications professional and was previously head of investor relations at Shire for 11 years.

Sep 23, 2019

MedGenome: Andy Peterson

MedGenome has appointed Andy Peterson as the firm's CSO. Prior to joining MedGenome, Peterson served as senior director of molecular biology at Genentech. As part of the GenomeAsia 100K consortium, Peterson led scientific efforts that produced a catalog of genetic variation across Asia. 

Sep 23, 2019

Fluidic Analytics: Joe Keegan

Fluidic Analytics has appointed Joe Keegan as the firm's chairman. Keegan currently serves on the boards of Bio-Techne and Interpace Diagnostics, as well as a number of early- and growth-stage companies in the life sciences tools and diagnostic industries. Prior to Fluidic Analytics, Keegan served as CEO as ForteBio until it was sold to Pall Corporation. Before ForteBio, Keegan was CEO of Molecular Devices. Keegan has also held the role of chairman of the Analytical Life Science & Diagnostics Association, non-executive chairman of Labcyte, and non-executive director of Advanced Cellular Diagnostics, ProteinSimple, and Seahorse Bioscience.

Sep 23, 2019

Precision BioSciences: David Thomson

Precision BioSciences has appointed David Thomson as chief operating officer. Thomson currently serves as the firm's chief development officer. Prior to Precision, Thomson served as senior VP of research and nonclinical development, for Shire. He also served as senior VP and global head for research and development operations at Shire. 

Sep 23, 2019

Illumina: Joydeep Goswami

Illumina has appointed Joydeep Goswami as senior VP of corporate development and strategic planning. Reporting to CEO Francis de Souza, he will be responsible for planning, strategic partnerships and acquisitions.

Goswami brings more than 20 years' experience in new product development, partnerships, licensing, and mergers and acquisitions. He comes to Illumina from Thermo Fisher Scientific, where he was president of the clinical next-generation sequencing and oncology business unit. He has also held leadership positions at Life Technologies and Invitrogen. He holds a doctorate in chemical engineering and an MBA from the Massachusetts Institute of Technology.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.